ALNYLAM PHARMACEUTICALS, INC. (ALNY) vs Moderna, Inc. (MRNA)
Side-by-side comparison from SEC filings: latest annual financials, insider activity and institutional ownership.
| Metric | ALNY | MRNA |
|---|---|---|
| Sector | Health Care | Health Care |
| Latest fiscal year | FY2025 | FY2025 |
| Revenue | $3.71B | $1.94B |
| Revenue growth (YoY) | ▲ 65.2% | ▼ 39.9% |
| Net income | $313.75M | -$2.82B |
| Gross margin | 81.8% | 55.3% |
| Diluted EPS | $2.33 | $-7.26 |
| Insider net (6 mo) | +15.8K sh • 2 sells • 0 buys | +421.8K sh • 11 sells • 0 buys |
| Institutional owners | 46 | 43 |
| Institutional value held | $29.35B | $19.58B |
| Next earnings (est.) | Around Oct 29, 2026 | Around Nov 5, 2026 |
Figures from each company's SEC filings (latest reported fiscal year; fiscal calendars may differ). Next-earnings dates are estimates from historical filing patterns.
About ALNYLAM PHARMACEUTICALS, INC. (ALNY)
Alnylam Pharmaceuticals is a global commercial-stage biopharmaceutical company that develops novel therapeutics based on RNA interference (RNAi), a naturally occurring biological pathway used to silence disease-causing genes by targeting messenger RNA before… Read more →
About Moderna, Inc. (MRNA)
Moderna is a biotechnology company and pioneer in mRNA medicine, using its integrated mRNA, lipid nanoparticle (LNP) delivery, and manufacturing platform to develop vaccines and therapeutics across infectious disease, oncology, and rare disease. Read more →
Source: SEC EDGAR.